A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

Yoon Jin Cha; Byoung Chul Cho; Hye Ryun Kim; Hye-Jeong Lee; Hyo Sup Shim

doi:10.1016/j.jtho.2015.12.097

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib

J Thorac Oncol. 2016 May;11(5):e55-e58. doi: 10.1016/j.jtho.2015.12.097. Epub 2015 Dec 29.

Authors

Yoon Jin Cha¹, Byoung Chul Cho², Hye Ryun Kim², Hye-Jeong Lee³, Hyo Sup Shim⁴

Affiliations

¹ Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
² Department of Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
³ Department of Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
⁴ Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: [email protected].

PMID: 26752677
DOI: 10.1016/j.jtho.2015.12.097

Abstract

Histologic changes can be involved in resistance to anticancer drugs. Transformation to small cell lung carcinoma (SCLC) following treatment with EGFR tyrosine kinase inhibitors has been reported in patients with EGFR-mutant lung adenocarcinoma. Herein, we report a case of ALK-rearranged lung adenocarcinoma with SCLC-like histology in a metastatic abdominal nodule that was resistant to crizotinib therapy.

Keywords: Anaplastic lymphoma kinase; Crizotinib; Lung adenocarcinoma; Resistance; Small cell lung carcinoma.

Publication types

Case Reports

MeSH terms

Abdominal Neoplasms / drug therapy
Abdominal Neoplasms / genetics*
Abdominal Neoplasms / secondary
Adenocarcinoma / drug therapy
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Aged
Anaplastic Lymphoma Kinase
Cell Transformation, Neoplastic / drug effects
Cell Transformation, Neoplastic / genetics*
Cell Transformation, Neoplastic / pathology
Crizotinib
Drug Resistance, Neoplasm / genetics*
Gene Rearrangement*
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Protein Kinase Inhibitors / pharmacology
Pyrazoles / pharmacology*
Pyridines / pharmacology*
Receptor Protein-Tyrosine Kinases / genetics*
Small Cell Lung Carcinoma / drug therapy
Small Cell Lung Carcinoma / genetics*
Small Cell Lung Carcinoma / pathology

Substances

Protein Kinase Inhibitors
Pyrazoles
Pyridines
Crizotinib
ALK protein, human
Anaplastic Lymphoma Kinase
Receptor Protein-Tyrosine Kinases